Trial Profile
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms MAIA
- Sponsors Janssen Research & Development; Janssen-Cilag
- 08 Mar 2024 This trial has been Completed in Austria.
- 01 Feb 2024 This trial has been completed in Belgium and Ireland.
- 19 Jan 2024 This trial has been completed in Denmark.